|
1
|
Lai CC, Shih TP, Ko WC, Tang HJ and Hsueh
PR: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
and coronavirus disease-2019 (COVID-19): The epidemic and the
challenges. Int J Antimicrob Agents. 55:1059242020. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Fehr AR and Perlman S: Coronaviruses: An
overview of their replication and pathogenesis. Methods Mol Biol.
1282:1–23. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chen Y, Liu Q and Guo D: Emerging
coronaviruses: Genome structure, replication, and pathogenesis. J
Med Virol. 92:418–423. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tsatsakis A, Petrakis D, Nikolouzakis TK,
Docea AO, Calina D, Vinceti M, Goumenou M, Kostoff RN, Mamoulakis
C, Aschner M and Hernández AF: COVID-19 an opportunity to
reevaluate the correlation between long-term effects of
anthropogenic pollutants on viral epidemic/pandemic events and
prevalence. Food Chem Toxicol. In Press.
|
|
5
|
Goumenou M, Sarigiannis D, Tsatsakis A,
Anesti O, Docea AO, Petrakis D, Tsoukalas D, Kostoff R, Rakitskii
V, Spandidos DA, et al: COVID-19 in Northern Italy: An integrative
overview of factors possibly influencing the sharp increase of the
outbreak (Review). Mol Med Rep. 22:20–32. 2020.PubMed/NCBI
|
|
6
|
Xu Z, Shi L, Wang Y, Zhang J, Huang L,
Zhang C, Liu S, Zhao P, Liu H, Zhu L, et al: Pathological findings
of COVID-19 associated with acute respiratory distress syndrome.
Lancet Respir Med. 8:420–422. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Li X, Geng M, Peng Y, Meng L and Lu S:
Molecular immune pathogenesis and diagnosis of COVID-19. J Pharm
Anal. 10:102–108. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Docea AO, Tsatsakis A, Albulescu D,
Cristea O, Zlatian O, Vinceti M, Moschos SA, Tsoukalas D, Goumenou
M, Drakoulis N, et al: A new threat from an old enemy: Re-emergence
of coronavirus (Review). Int J Mol Med. 45:1631–1643.
2020.PubMed/NCBI
|
|
9
|
Paules CI, Marston HD and Fauci AS:
Coronavirus infections - more than just the common cold. JAMA.
323:7072020. View Article : Google Scholar
|
|
10
|
Lu R, Zhao X, Li J, Niu P, Yang B, Wu H,
Wang W, Song H, Huang B, Zhu N, et al: Genomic characterisation and
epidemiology of 2019 novel coronavirus: Implications for virus
origins and receptor binding. Lancet. 395:565–574. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhou P, Yang XL, Wang XG, Hu B, Zhang L,
Zhang W, Si HR, Zhu Y, Li B, Huang CL, et al: A pneumonia outbreak
associated with a new coronavirus of probable bat origin. Nature.
579:270–273. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wu A, Peng Y, Huang B, Ding X, Wang X, Niu
P, Meng J, Zhu Z, Zhang Z, Wang J, et al: Genome composition and
divergence of the Novel Coronavirus (2019-nCoV) originating in
China. Cell Host Microbe. 27:325–328. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Knoops K, Kikkert M, Worm SH,
Zevenhoven-Dobbe JC, van der Meer Y, Koster AJ, Mommaas AM and
Snijder EJ: SARS-coronavirus replication is supported by a
reticulovesicular network of modified endoplasmic reticulum. PLoS
Biol. 6:e2262008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Alsaadi EA and Jones IM: Membrane binding
proteins of coronaviruses. Future Virol. 14:275–286. 2019.
View Article : Google Scholar
|
|
15
|
Robbins M, Judge A, Liang L, McClintock K,
Yaworski E and MacLachlan I: 2′-O-methyl-modified RNAs act as TLR7
antagonists. Mol Ther. 15:1663–1669. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kikkert M: Innate immune evasion by human
respiratory RNA viruses. J Innate Immun. 12:4–20. 2020. View Article : Google Scholar :
|
|
17
|
Gordon DE, Jang GM, Bouhaddou M, Xu J,
Obernier K, White KM, O′Meara MJ, Rezelj VV, Guo JZ, Swaney DL, et
al: A SARS-CoV-2 protein interaction map reveals targets for drug
repurposing. Nature. https://doi.org/10.1038/s41586-020-2286-9.
|
|
18
|
Wrapp D, Wang N, Corbett KS, Goldsmith JA,
Hsieh CL, Abiona O, Graham BS and McLellan JS: Cryo-EM structure of
the 2019-nCoV spike in the prefusion conformation. Science.
367:1260–1263. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
To KF and Lo AWI: Exploring the
pathogenesis of severe acute respiratory syndrome (SARS): The
tissue distribution of the coronavirus (SARS-CoV) and its putative
receptor, angiotensin-converting enzyme 2 (ACE2). J Pathol.
203:740–743. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hamming I, Timens W, Bulthuis MLC, Lely
AT, Navis G and van Goor H: Tissue distribution of ACE2 protein,
the functional receptor for SARS coronavirus. A first step in
understanding SARS pathogenesis. J Pathol. 203:631–637. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hoffmann M, Kleine-Weber H, Schroeder S,
Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH,
Nitsche A, et al: SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2
and is blocked by a clinically proven protease inhibitor. Cell.
181:271–280.e8. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sawicki SG, Sawicki DL and Siddell SG: A
contemporary view of coronavirus transcription. J Virol. 81:20–29.
2007. View Article : Google Scholar :
|
|
23
|
Rabi FA, Al Zoubi MS, Kasasbeh GA, Salameh
DM and Al-Nasser AD: Sars-cov-2 and coronavirus disease 2019: What
we know so far. Pathogens. 9:E2312020. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gribble J, Pruijssers AJ, Agostini ML,
Anderson-Daniels J, Chappell JD, Lu X, Stevens LJ, Routh AL and
Denison MR: The coronavirus proofreading exoribonuclease mediates
extensive viral recombination. bioRxiv: https://doi.org/10.1101/2020.04.23057786.
|
|
25
|
Ferron F, Subissi L, Silveira De Morais
AT, Le NTT, Sevajol M, Gluais L, Decroly E, Vonrhein C, Bricogne G,
Canard B, et al: Structural and molecular basis of mismatch
correction and ribavirin excision from coronavirus RNA. Proc Natl
Acad Sci USA. 115:E162–E171. 2018. View Article : Google Scholar
|
|
26
|
Forster P, Forster L, Renfrew C and
Forster M: Phylogenetic network analysis of SARS-CoV-2 genomes.
Proc Natl Acad Sci USA. 117:9241–9243. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tang X, Wu C, Li X, Song Y, Yao X, Wu X,
Duan Y, Zhang H, Wang Y, Qian Z, et al: On the origin and
continuing evolution of SARS-CoV-2. Natl Sci Rev. nwaa0362020.
|
|
28
|
Korber B, Fischer W, Gnanakaran SG, Yoon
H, Theiler J, Abfalterer W, Foley B, Giorgi EE, Bhattacharya T,
Parker MD, et al: Spike mutation pipeline reveals the emergence of
a more transmissible form of SARS-CoV-2. bioRxiv: https://.org/10.1101/2020.04.29069054.
|
|
29
|
van Dorp L, Acman M, Richard D, Shaw LP,
Ford CE, Ormond L, Owen CJ, Pang J, Tan CCS, Boshier FAT, et al:
Emergence of genomic diversity and recurrent mutations in
SARS-CoV-2. Infect Genet Evol. May 5–2020.Epub ahead of print.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bilinska K, Jakubowska P, Von Bartheld CS
and Butowt R: Expression of the SARS-CoV-2 entry proteins, ACE2 and
TMPRSS2, in cells of the olfactory epithelium: identification of
cell types and trends with age. ACS Chem Neurosci. May 7–2020.Epub
ahead of print. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ziegler CGK, Allon SJ, Nyquist SK, Mbano
IM, Miao VN, Tzouanas CN, Cao Y, Yousif AS, Bals J and Hauser BM:
SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human
airway epithelial cells and is detected in specific cell subsets
across tissues. Cell. https://doi.org/10.1016/j.cell.2020.04.035.
|
|
32
|
Moschos SA, Frick M, Taylor B, Turnpenny
P, Graves H, Spink KG, Brady K, Lamb D, Collins D, Rockel TD, et
al: Uptake, efficacy, and systemic distribution of naked, inhaled
short interfering RNA (siRNA) and locked nucleic acid (LNA)
antisense. Mol Ther. 19:2163–2168. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Di Pasquale G and Chiorini JA: AAV
transcytosis through barrier epithelia and endothelium. Mol Ther.
13:506–516. 2006. View Article : Google Scholar
|
|
34
|
Lin L, Lu L, Cao W and Li T: Hypothesis
for potential pathogenesis of SARS-CoV-2 infection - a review of
immune changes in patients with viral pneumonia. Emerg Microbes
Infect. 9:727–732. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wu Y, Guo C, Tang L, Hong Z, Zhou J, Dong
X, Yin H, Xiao Q, Tang Y, Qu X, et al: Prolonged presence of
SARS-CoV-2 viral RNA in faecal samples. Lancet Gastroenterol
Hepatol. 5:434–435. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Xiao F, Tang M, Zheng X, Liu Y, Li X and
Shan H: Evidence for gastrointestinal infection of SARS-CoV-2.
Gastroenterology. 158:1831–1833.e3. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Song C, Wang Y, Li W, Hu B, Chen G, Xia P,
Wang W, Li C, Hu Z, Yang X, et al: Detection of 2019 novel
coronavirus in semen and testicular biopsy specimen of COVID-19
patients. medRxiv: :https://doi.org/10.1101/2020.03.31.20042333.
|
|
38
|
Chen Y and Li L: SARS-CoV-2: Virus
dynamics and host response. Lancet Infect Dis. 20:515–516. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Yi Y, Lagniton PNP, Ye S, Li E and Xu RH:
COVID-19: What has been learned and to be learned about the novel
coronavirus disease. Int J Biol Sci. 16:1753–1766. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Shi Y, Wang Y, Shao C, Huang J, Gan J,
Huang X, Bucci E, Piacentini M, Ippolito G and Melino G: COVID-19
infection: The perspectives on immune responses. Cell Death Differ.
27:1451–1454. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Guo L, Ren L, Yang S, Xiao M, Chang D,
Yang F, Dela Cruz CS, Wang Y, Wu C, Xiao Y, et al: Profiling early
humoral response to diagnose novel Coronavirus Disease (COVID-19).
Clin Infect Dis ciaa. 310:2020.
|
|
42
|
To KKW, Tsang OTY, Leung WS, Tam AR, Wu
TC, Lung DC, Yip CC, Cai JP, Chan JM, Chik TS, et al: Temporal
profiles of viral load in posterior oropharyngeal saliva samples
and serum antibody responses during infection by SARS-CoV-2: An
observational cohort study. Lancet Infect Dis. 20:565–574. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Cao Z, Liu L, Du L, Zhang C, Jiang S, Li T
and He Y: Potent and persistent antibody responses against the
receptor-binding domain of SARS-CoV spike protein in recovered
patients. Virol J. 7:2992010. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Calina D, Docea AO, Petrakis D, Egorov A
M, Ishmukhametov AA, Gabibov AG, Shtilman MI, Kostoff R, Carvalho
F, Vinceti M, et al: Towards effective COVID-19 vaccines: Updates,
perspectives and challenges (Review). Int J Mol Med. 46:3–16.
2020.
|
|
45
|
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu
Y, Zhang L, Fan G, Xu J, Gu X, et al: Clinical features of patients
infected with 2019 novel coronavirus in Wuhan, China. Lancet.
395:497–506. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Wang F, Nie J, Wang H, Zhao Q, Xiong Y,
Deng L, Song S, Ma Z, Mo P and Zhang Y: Characteristics of
peripheral lymphocyte subset alteration in COVID-19 pneumonia. J
Infect Dis. 221:1762–1769. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Tu YF, Chien CS, Yarmishyn AA, Lin YY, Luo
YH, Lin YT, Lai WY, Yang DM, Chou SJ, Yang YP, et al: A Review of
SARS-CoV-2 and the Ongoing Clinical Trials. Int J Mol Sci.
21:212020. View Article : Google Scholar
|
|
48
|
Wu C, Liu Y, Yang Y, Zhang P, Zhong W,
Wang Y, Wang Q, Xu Y, Li M, Li X, et al: Analysis of therapeutic
targets for SARS-CoV-2 and discovery of potential drugs by
computational methods. Acta Pharm Sin B. Feb 27–2020.Epub ahead of
print. View Article : Google Scholar
|
|
49
|
Shojaei A and Salari P: COVID-19 and off
label use of drugs: An ethical viewpoint. Daru. May 8–2020.Epub
ahead of print. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Senanayake SL: Drug repurposing strategies
for COVID-19. Future Drug Discov: fdd-2020-0010. 2020. View Article : Google Scholar
|
|
51
|
Sanders JM, Monogue ML, Jodlowski TZ and
Cutrell JB: Pharmacologic treatments for coronavirus disease 2019
(COVID-19): A Review. JAMA. 323:1824–1836. 2020.
|
|
52
|
Haschke M, Schuster M, Poglitsch M,
Loibner H, Salzberg M, Bruggisser M, Penninger J and Krähenbühl S:
Pharmacokinetics and pharmacodynamics of recombinant human
angio-tensin-converting enzyme 2 in healthy human subjects. Clin
Pharmacokinet. 52:783–792. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Wilkins MR, Aman J, Harbaum L, Ulrich A,
Wharton J and Rhodes CJ: Recent advances in pulmonary arterial
hypertension. F1000Research. 7:F1000 Faculty Rev- 1128. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Khan A, Benthin C, Zeno B, Albertson TE,
Boyd J, Christie JD, Hall R, Poirier G, Ronco JJ, Tidswell M, et
al: A pilot clinical trial of recombinant human
angiotensin-converting enzyme 2 in acute respiratory distress
syndrome. Crit Care. 21:2342017. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Batlle D, Wysocki J and Satchell K:
Soluble angiotensin-converting enzyme 2: A potential approach for
coronavirus infection therapy? Clin Sci (Lond). 134:543–545. 2020.
View Article : Google Scholar
|
|
56
|
US National Library of Medicine:
Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a
Treatment for Patients With COVID-19 (APN01-COVID-19). http://ClinicalTrials.gov
Identifier: NCT04335136. https://clinicaltrials.gov/ct2/show/NCT04335136?term=NCT04335136&draw=2amp;rank=1.
Accessed April 6, 2020.
|
|
57
|
Han Y and Král P: Computational design of
ACE2-based peptide inhibitors of SARS-CoV-2. ACS Nano.
14:5143–5147. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Heinemann L, Baughman R, Boss A and
Hompesch M: Pharmacokinetic and pharmacodynamic properties of a
novel inhaled insulin. J Diabetes Sci Technol. 11:148–156. 2017.
View Article : Google Scholar :
|
|
59
|
Deng J, Wang D-X, Deng W, Li C-Y and Tong
J: The effect of endogenous angiotensin II on alveolar fluid
clearance in rats with acute lung injury. Can Respir J. 19:311–318.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Hernández Prada JA, Ferreira AJ, Katovich
MJ, Shenoy V, Qi Y, Santos RA, Castellano RK, Lampkins AJ, Gubala
V, Ostrov DA, et al: Structure-based identification of
small-molecule angiotensin-converting enzyme 2 activators as novel
antihypertensive agents. Hypertension. 51:1312–1317. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Qi Y, Zhang J, Cole-Jeffrey CT, Shenoy V,
Espejo A, Hanna M, Song C, Pepine CJ, Katovich MJ and Raizada MK:
Diminazene aceturate enhances angiotensin-converting enzyme 2
activity and attenuates ischemia-induced cardiac pathophysiology.
Hypertension. 62:746–752. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Qaradakhi T, Gadanec LK, McSweeney KR,
Tacey A, Apostolopoulos V, Levinger I, Rimarova K, Egom EE, Rodrigo
L, Kruzliak P, et al: The potential actions of
angiotensin-converting enzyme II (ACE2) activator diminazene
aceturate (DIZE) in various diseases. Clin Exp Pharmacol Physiol.
47:751–758. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Gurwitz D: Angiotensin receptor blockers
as tentative SARS-CoV-2 therapeutics. Drug Dev Res. Mar 4–2020.Epub
ahead of print. View Article : Google Scholar
|
|
64
|
Ishikura H, Nishimura S, Matsunami M,
Tsujiuchi T, Ishiki T, Sekiguchi F, Naruse M, Nakatani T, Kamanaka
Y and Kawabata A: The proteinase inhibitor camostat mesilate
suppresses pancreatic pain in rodents. Life Sci. 80:1999–2004.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Zhou Y, Vedantham P, Lu K, Agudelo J,
Carrion R Jr, Nunneley JW, Barnard D, Pöhlmann S, McKerrow JH,
Renslo AR, et al: Protease inhibitors targeting coronavirus and
filovirus entry. Antiviral Res. 116:76–84. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Kawase M, Shirato K, van der Hoek L,
Taguchi F and Matsuyama S: Simultaneous treatment of human
bronchial epithelial cells with serine and cysteine protease
inhibitors prevents severe acute respiratory syndrome coronavirus
entry. J Virol. 86:6537–6545. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Tarnow C, Engels G, Arendt A, Schwalm F,
Sediri H, Preuss A, Nelson PS, Garten W, Klenk HD, Gabriel G, et
al: TMPRSS2 is a host factor that is essential for pneumotropism
and pathogenicity of H7N9 influenza A virus in mice. J Virol.
88:4744–4751. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Fuwa M, Kageyama M, Ohashi K, Sasaoka M,
Sato R, Tanaka M and Tashiro K: Nafamostat and sepimostat
identified as novel neuroprotective agents via NR2B
N-methyl-D-aspartate receptor antagonism using a rat retinal
excitotoxicity model. Sci Rep. 9:204092019. View Article : Google Scholar
|
|
69
|
Yamamoto M, Matsuyama S, Li X, Takeda M,
Kawaguchi Y, Inoue JI and Matsuda Z: Identification of Nafamostat
as a potent inhibitor of Middle East Respiratory Syndrome
Coronavirus S Protein-mediated membrane fusion using the
Split-Protein-Based Cell-Cell Fusion Assay. Antimicrob Agents
Chemother. 60:6532–6539. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Wang M, Cao R, Zhang L, Yang X, Liu J, Xu
M, Shi Z, Hu Z, Zhong W and Xiao G: Remdesivir and chloroquine
effectively inhibit the recently emerged novel coronavirus
(2019-nCoV) in vitro. Cell Res. 30:269–271. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Lee YK, Lee HW, Choi KH and Kim BS:
Ability of nafamostat mesilate to prolong filter patency during
continuous renal replacement therapy in patients at high risk of
bleeding: A randomized controlled study. PLoS One. 9:e1087372014.
View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Lucas JM, Heinlein C, Kim T, Hernandez SA,
Malik MS, True LD, Morrissey C, Corey E, Montgomery B, Mostaghel E,
et al: The androgen-regulated protease TMPRSS2 activates a
proteolytic cascade involving components of the tumor
microenvironment and promotes prostate cancer metastasis. Cancer
Discov. 4:1310–1325. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Laporte M and Naesens L: Airway proteases:
An emerging drug target for influenza and other respiratory virus
infections. Curr Opin Virol. 24:16–24. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Maggio R and Corsini GU: Repurposing the
mucolytic cough suppressant and TMPRSS2 protease inhibitor
bromhexine for the prevention and management of SARS-CoV-2
infection. Pharmacol Res. 157:1048372020. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Zhirnov OP, Matrosovich TY, Matrosovich MN
and Klenk HD: Aprotinin, a protease inhibitor, suppresses
proteolytic activation of pandemic H1N1v influenza virus. Antivir
Chem Chemother. 21:169–174. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Bojkova D, McGreig JE, McLaughlin KM,
Masterson SG, Widera M, Krähling V, Ciesek S, Wass MN, Michaelis M
and Cinatl J Jr: SARS-CoV-2 and SARS-CoV differ in their cell
tropism and drug sensitivity profiles. bioRxiv: :https://doi.org/10.1101/2020.04.03024257.
|
|
77
|
Chen Z, Mi L, Xu J, Yu J, Wang X, Jiang J,
Xing J, Shang P, Qian A, Li Y, et al: Function of HAb18G/CD147 in
invasion of host cells by severe acute respiratory syndrome
coronavirus. J Infect Dis. 191:755–760. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Watanabe A, Yoneda M, Ikeda F, Terao-Muto
Y, Sato H and Kai C: CD147/EMMPRIN acts as a functional entry
receptor for measles virus on epithelial cells. J Virol.
84:4183–4193. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Lythgoe MP and Middleton P: Ongoing
Clinical Trials for the Management of the COVID-19 Pandemic. Trends
Pharmacol Sci. Apr 9–2020.Epub ahead of print. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Inoue Y, Tanaka N, Tanaka Y, Inoue S,
Morita K, Zhuang M, Hattori T and Sugamura K: Clathrin-dependent
entry of severe acute respiratory syndrome coronavirus into target
cells expressing ACE2 with the cytoplasmic tail deleted. J Virol.
81:8722–8729. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Choy KT, Wong AYL, Kaewpreedee P, Sia SF,
Chen D, Hui KPY, Chu DKW, Chan MCW, Cheung PP, Huang X, et al:
Remdesivir, lopinavir, emetine, and homoharringtonine inhibit
SARS-CoV-2 replication in vitro. Antiviral Res. 178:1047862020.
View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Stebbing J, Phelan A, Griffin I, Tucker C,
Oechsle O, Smith D and Richardson P: COVID-19: Combining antiviral
and anti-inflammatory treatments. Lancet Infect Dis. 20:400–402.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Conner SD and Schmid SL: Identification of
an adaptor-associated kinase, AAK1, as a regulator of
clathrin-mediated endocytosis. J Cell Biol. 156:921–929. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Sorrell FJ, Szklarz M, Abdul Azeez KR,
Elkins JM and Knapp S: Family-wide structural analysis of human
Numb-associated protein kinases. Structure. 24:401–411. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Eberl HC, Werner T, Reinhard FB, Lehmann
S, Thomson D, Chen P, Zhang C, Rau C, Muelbaier M, Drewes G, et al:
Chemical proteomics reveals target selectivity of clinical Jak
inhibitors in human primary cells. Sci Rep. 9:141592019. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Ou X, Liu Y, Lei X, Li P, Mi D, Ren L, Guo
L, Guo R, Chen T, Hu J, et al: Characterization of spike
glycoprotein of SARS-CoV-2 on virus entry and its immune
cross-reactivity with SARS-CoV. Nat Commun. 11:16202020. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Dana D and Pathak SK: A review of small
molecule inhibitors and functional probes of human Cathepsin L.
Molecules. 25:6982020. View Article : Google Scholar :
|
|
88
|
Cossart P and Helenius A: Endocytosis of
viruses and bacteria. Cold Spring Harb Perspect Biol.
6:a0169722014. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Nicola AV, McEvoy AM and Straus SE: Roles
for endocytosis and low pH in herpes simplex virus entry into HeLa
and Chinese hamster ovary cells. J Virol. 77:5324–5332. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Touret F and de Lamballerie X: Of
chloroquine and COVID-19. Antiviral Res. 177:1047622020. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Yao X, Ye F, Zhang M, Cui C, Huang B, Niu
P, Liu X, Zhao L, Dong E, Song C, et al: In vitro antiviral
activity and projection of optimized dosing design of
hydroxychloroquine for the treatment of severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. Mar
9–2020.Epub ahead of print. View Article : Google Scholar :
|
|
92
|
Devaux CA, Rolain JM, Colson P and Raoult
D: New insights on the antiviral effects of chloroquine against
coronavirus: What to expect for COVID-19? Int J Antimicrob Agents.
Mar 12–2020.Epub ahead of print. View Article : Google Scholar
|
|
93
|
Biot C, Daher W, Chavain N, Fandeur T,
Khalife J, Dive D and De Clercq E: Design and synthesis of
hydroxyferroquine derivatives with antimalarial and antiviral
activities. J Med Chem. 49:2845–2849. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
de Wilde AH, Jochmans D, Posthuma CC,
Zevenhoven-Dobbe JC, van Nieuwkoop S, Bestebroer TM, van den Hoogen
BG, Neyts J and Snijder EJ: Screening of an FDA-approved compound
library identifies four small-molecule inhibitors of Middle East
respiratory syndrome coronavirus replication in cell culture.
Antimicrob Agents Chemother. 58:4875–4884. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Vincent MJ, Bergeron E, Benjannet S,
Erickson BR, Rollin PE, Ksiazek TG, Seidah NG and Nichol ST:
Chloroquine is a potent inhibitor of SARS coronavirus infection and
spread. Virol J. 2:692005. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Cortegiani A, Ingoglia G, Ippolito M,
Giarratano A and Einav S: A systematic review on the efficacy and
safety of chloroquine for the treatment of COVID-19. J Crit Care.
Mar 10–2020.Epub ahead of print. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Gao J, Tian Z and Yang X: Breakthrough:
Chloroquine phosphate has shown apparent efficacy in treatment of
COVID-19 associated pneumonia in clinical studies. Biosci Trends.
14:72–73. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Guangdong Provincial Department of Science
and Technology and Guangdong Provincial Health Commission
Multi-center Collaborative Group of chloroquine phosphate for the
treatment of New Coronavirus Pneumonia: Expert consensus on the
treatment of new coronavirus pneumonia with chloroquine phosphate.
Zhonghua Jie He He Hu Xi Za Zhi. 43:185–188. 2020.
|
|
99
|
Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H,
Li Y, Hu Z, Zhong W and Wang M: Hydroxychloroquine, a less toxic
derivative of chloroquine, is effective in inhibiting SARS-CoV-2
infection in vitro. Cell Discov. 6:162020. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Chen Z, Hu J and Zhang Z, Jiang S, Han S,
Yan D, Zhuang R, Hu B and Zhang Z: Efficacy of hydroxychloroquine
in patients with COVID-19: results of a randomized clinical trial.
medRxiv: :https://doi.org/10.1101/2020.03.22.20040758.
|
|
101
|
Gautret P, Lagier JC, Parola P, Hoang VT,
Meddeb L, Mailhe M, Doudier B, Courjon J, Giordanengo V, Vieira VE,
et al: Hydroxychloroquine and azithromycin as a treatment of
COVID-19: Results of an open-label non-randomized clinical trial.
Int J Antimicrob Agents. Mar 20–2020.Epub ahead of print.
View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Hickley NM, Al-Maskari A and McKibbin M:
Chloroquine and hydroxychloroquine toxicity. Arch Ophthalmol.
129:1506–1507. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Taccone FS, Gorham J and Vincent JL:
Hydroxychloroquine in the management of critically ill patients
with COVID-19: The need for an evidence base. Lancet Respir Med.
Apr 15–2020.Epub ahead of print. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Magagnoli J, Narendran S, Pereira F,
Cummings T, Hardin JW, Sutton SS and Ambati J: Outcomes of
hydroxychloroquine usage in United States veterans hospitalized
with Covid-19. medRxiv: :https://doi.org/10.1101/2020.04.16.20065920.
|
|
105
|
Xue X, Yu H, Yang H, Xue F, Wu Z, Shen W,
Li J, Zhou Z, Ding Y, Zhao Q, et al: Structures of two coronavirus
main proteases: implications for substrate binding and antiviral
drug design. J Virol. 82:2515–2527. 2008. View Article : Google Scholar :
|
|
106
|
Hall DC Jr and Ji HF: A search for
medications to treat COVID-19 via in silico molecular docking
models of the SARS-CoV-2 spike glycoprotein and 3CL protease.
Travel Med Infect Dis. Apr 12–2020.Epub ahead of print. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Zhang L, Lin D, Kusov Y, Nian Y, Ma Q,
Wang J, von Brunn A, Leyssen P, Lanko K, Neyts J, et al:
α-Ketoamides as broad-spectrum inhibitors of coronavirus and
enterovirus replication: structure-based design, synthesis, and
activity assessment. J Med Chem. 63:4562–4578. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Zhang L, Lin D, Sun X, Curth U, Drosten C,
Sauerhering L, Becker S, Rox K and Hilgenfeld R: Crystal structure
of SARS-CoV-2 main protease provides a basis for design of improved
α-ketoamide inhibitors. Science. 368:409–412. 2020.PubMed/NCBI
|
|
109
|
Croxtall JD and Perry CM:
Lopinavir/Ritonavir: A review of its use in the management of HIV-1
infection. Drugs. 70:1885–1915. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Chen F, Chan KH, Jiang Y, Kao RY, Lu HT,
Fan KW, Cheng VC, Tsui WH, Hung IF and Lee TS: In vitro
susceptibility of 10 clinical isolates of SARS coronavirus to
selected antiviral compounds. J Clin Virol. 31:69–75. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Yamamoto N, Matsuyama S, Hoshino T and
Yamamoto N: Nelfinavir inhibits replication of severe acute
respiratory syndrome coronavirus 2 in vitro. bioRxiv: :https://doi.org/10.1101/2020.04.06026476.
|
|
112
|
Cao B, Wang Y, Wen D, Liu W, Wang J, Fan
G, Ruan L, Song B, Cai Y, Wei M, et al: A Trial of
Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N
Engl J Med. 382:1787–1799. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Boopathi S, Poma AB and Kolandaivel P:
Novel 2019 coronavirus structure, mechanism of action, antiviral
drug promises and rule out against its treatment. J Biomol Struct
Dyn. Apr 30–2020.Epub ahead of print. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Yamamoto N, Yang R, Yoshinaka Y, Amari S,
Nakano T, Cinatl J, Rabenau H, Doerr HW, Hunsmann G, Otaka A, et
al: HIV protease inhibitor nelfinavir inhibits replication of
SARS-associated coronavirus. Biochem Biophys Res Commun.
318:719–725. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Fintelman-Rodrigues N, Sacramento CQ, Lima
CR, da Silva FS, Ferreira AC, Mattos M, de Freitas CS, Soares VC,
da Silva Gomes Dias S, Temerozo JR, et al: Atazanavir inhibits
SARS-CoV-2 replication and pro-inflammatory cytokine production.
bioRxiv: :https://doi.org/10.1101/2020.04.04020925.
|
|
116
|
Agostini ML, Andres EL, Sims AC, Graham
RL, Sheahan TP, Lu X, Smith EC, Case JB, Feng JY, Jordan R, et al:
Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is
mediated by the viral polymerase and the proofreading
exoribonuclease. MBio. 9:e00221–e18. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Gao Y, Yan L, Huang Y, Liu F, Zhao Y, Cao
L, Wang T, Sun Q, Ming Z, Zhang L, et al: Structure of the
RNA-dependent RNA polymerase from COVID-19 virus. Science. Apr
10–2020.Epub ahead of print. View Article : Google Scholar
|
|
118
|
Smith EC: The not-so-infinite malleability
of RNA viruses: Viral and cellular determinants of RNA virus
mutation rates. PLoS Pathog. 13:e1006254. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Smith EC, Blanc H, Surdel MC, Vignuzzi M
and Denison MR: Coronaviruses lacking exoribonuclease activity are
susceptible to lethal mutagenesis: Evidence for proofreading and
potential therapeutics. PLoS Pathog. 9:e1003565. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Becares M, Pascual-Iglesias A, Nogales A,
Sola I, Enjuanes L and Zuñiga S: Mutagenesis of Coronavirus nsp14
reveals its potential role in modulation of the innate immune
response. J Virol. 90:5399–5414. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
De Clercq E and Li G: DC approved
antiviral drugs over the past 50 years. Clin Microbiol Rev.
29:695–747. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Elfiky AA: Ribavirin, Remdesivir,
Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA
dependent RNA polymerase (RdRp): A molecular docking study. Life
Sci. 253:1175922020. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Amirian ES and Levy JK: Current knowledge
about the antivirals remdesivir (GS-5734) and GS-441524 as
therapeutic options for coronaviruses. One Health. 9:1001282020.
View Article : Google Scholar : PubMed/NCBI
|
|
124
|
US Food and Drug Administration (FDA):
Recommendations for Investigational COVID-19 Convalescent Plasma.
https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ide-process-cber/recommendations-investigational-covid-19-convalescent-plasma.
Accessed May 1, 2020.
|
|
125
|
Mulangu S, Dodd LE, Davey RT Jr, Tshiani
Mbaya O, Proschan M, Mukadi D, Lusakibanza Manzo M, Nzolo D,
Tshomba Oloma A, Ibanda A, et al; PALM Writing Group. PALM
Consortium Study Team: A Randomized, Controlled Trial of Ebola
Virus Disease Therapeutics. N Engl J Med. 381:2293–2303. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Holshue ML, DeBolt C, Lindquist S, Lofy
KH, Wiesman J, Bruce H, Spitters C, Ericson K, Wilkerson S, Tural
A, et al: Washington State 2019-nCoV Case Investigation Team: First
Case of 2019 Novel Coronavirus in the United States. N Engl J Med.
382:929–936. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
COVID-19 Investigation Team: Clinical and
virologic characteristics of the first 12 patients with coronavirus
disease 2019 (COVID-19) in the United States. Nat Med. Apr
23–2020.Epub ahead of print.
|
|
128
|
Wang Y, Zhang D, Du G, Du R, Zhao J, Jin
Y, Fu S, Gao L, Cheng Z, Lu Q, et al: Remdesivir in adults with
severe COVID-19: A randomised, double-blind, placebo-controlled,
multicentre trial. Lancet. 395:P1569–P1578. 2020. View Article : Google Scholar
|
|
129
|
Furuta Y, Takahashi K, Kuno-Maekawa M,
Sangawa H, Uehara S, Kozaki K, Nomura N, Egawa H and Shiraki K:
Mechanism of action of T-705 against influenza virus. Antimicrob
Agents Chemother. 49:981–986. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Furuta Y, Gowen BB, Takahashi K, Shiraki
K, Smee DF and Barnard DL: Favipiravir (T-705), a novel viral RNA
polymerase inhibitor. Antiviral Res. 100:446–454. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Jordan PC, Stevens SK and Deval J:
Nucleosides for the treatment of respiratory RNA virus infections.
Antivir Chem Chemother. 26:20402066187644832018. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Madelain V, Nguyen THT, Olivo A, de
Lamballerie X, Guedj J, Taburet A-M and Mentré F: Ebola virus
infection: Review of the pharmacokinetic and pharmacodynamic
properties of drugs considered for testing in human efficacy
trials. Clin Pharmacokinet. 55:907–923. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Nagata T, Lefor AK, Hasegawa M and Ishii
M: Favipiravir: A new medication for the Ebola virus disease
pandemic. Disaster Med Public Health Prep. 9:79–81. 2015.
View Article : Google Scholar
|
|
134
|
Cai Q, Yang M, Liu D, Chen J, Shu D, Xia
J, Liao X, Gu Y, Cai Q, Yang Y, et al: Experimental Treatment with
Favipiravir for COVID-19: An Open-Label Control Study. Engineering
(Beijing). Mar 18–2020.Epub ahead of print.
|
|
135
|
Warren TK, Wells J, Panchal RG, Stuthman
KS, Garza NL, Van Tongeren SA, Dong L, Retterer CJ, Eaton BP,
Pegoraro G, et al: Protection against filovirus diseases by a novel
broad-spectrum nucleoside analogue BCX4430. Nature. 508:402–405.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Taylor R, Kotian P, Warren T, Panchal R,
Bavari S, Julander J, Dobo S, Rose A, El-Kattan Y, Taubenheim B, et
al: BCX4430 - A broad-spectrum antiviral adenosine nucleoside
analog under development for the treatment of Ebola virus disease.
J Infect Public Health. 9:220–226. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
De Clercq E: New nucleoside analogues for
the treatment of hemorrhagic fever virus infections. Chem Asian J.
14:3962–3968. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Sheahan TP, Sims AC, Zhou S, Graham RL,
Pruijssers AJ, Agostini ML, Leist SR, Schäfer A, Dinnon KH III,
Stevens LJ, et al: An orally bioavailable broad-spectrum antiviral
inhibits SARS-CoV-2 in human airway epithelial cell cultures and
multiple coronaviruses in mice. Sci Transl Med. 12:eabb58832020.
View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Agostini ML, Pruijssers AJ, Chappell JD,
Gribble J, Lu X, Andres EL, Bluemling GR, Lockwood MA, Sheahan TP,
Sims AC, et al: Small-molecule antiviral β-d-N4-Hydroxycytidine
inhibits a proofreading-intact Coronavirus with a high genetic
barrier to resistance. J Virol. 93:e01348–e19. 2019. View Article : Google Scholar :
|
|
140
|
Stockman LJ, Bellamy R and Garner P: SARS:
Systematic review of treatment effects. PLoS Med. 3:e343. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Moens U and Macdonald A: Effect of the
large and small T-antigens of human polyomaviruses on signaling
pathways. Int J Mol Sci. 20:202019. View Article : Google Scholar
|
|
142
|
Gassen NC, Niemeyer D, Muth D, Corman VM,
Martinelli S, Gassen A, Hafner K, Papies J, Mösbauer K, Zellner A,
et al: SKP2 attenuates autophagy through Beclin1-ubiquitination and
its inhibition reduces MERS-Coronavirus infection. Nat Commun.
10:57702019. View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Gassen NC, Papies J, Bajaj T, Dethloff F,
Emanuel J, Weckmann K, Heinz DE, Heinemann N, Lennarz M, Richter A,
et al: Analysis of SARS-CoV-2-controlled autophagy reveals
spermidine, MK-2206, and niclosamide as putative antiviral
therapeutics. bioRxiv: :https://doi.org/10.1101/2020.04.15.997254.
|
|
144
|
Mizutani T, Fukushi S, Saijo M, Kurane I
and Morikawa S: Importance of Akt signaling pathway for apoptosis
in SARS-CoV-infected Vero E6 cells. Virology. 327:169–174. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Nitulescu GM, Margina D, Juzenas P, Peng
Q, Olaru OT, Saloustros E, Fenga C, Spandidos DA, Libra M and
Tsatsakis AM: Akt inhibitors in cancer treatment: The long journey
from drug discovery to clinical use (Review). Int J Oncol.
48:869–885. 2016. View Article : Google Scholar :
|
|
146
|
Denisova OV, Söderholm S, Virtanen S, Von
Schantz C, Bychkov D, Vashchinkina E, Desloovere J, Tynell J,
Ikonen N, Theisen LL, et al: Akt inhibitor MK2206 prevents
influenza pH1N1 virus infection in vitro. Antimicrob Agents
Chemother. 58:3689–3696. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Kindrachuk J, Ork B, Hart BJ, Mazur S,
Holbrook MR, Frieman MB, Traynor D, Johnson RF, Dyall J, Kuhn JH,
et al: Antiviral potential of ERK/MAPK and PI3K/AKT/mTOR signaling
modulation for Middle East respiratory syndrome coronavirus
infection as identified by temporal kinome analysis. Antimicrob
Agents Chemother. 59:1088–1099. 2015. View Article : Google Scholar :
|
|
148
|
De Santi M, Baldelli G, Diotallevi A,
Galluzzi L, Schiavano GF and Brandi G: Metformin prevents cell
tumorigenesis through autophagy-related cell death. Sci Rep.
9:662019. View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Lehrer S: Inhaled biguanides and mTOR
inhibition for influenza and coronavirus (Review). World Acad Sci
J. 2:12020.PubMed/NCBI
|
|
150
|
Chen W, Mook RA Jr, Premont RT and Wang J:
Niclosamide: Beyond an antihelminthic drug. Cell Signal. 41:89–96.
2018. View Article : Google Scholar
|
|
151
|
Wu CJ, Jan JT, Chen CM, Hsieh HP, Hwang
DR, Liu HW, Liu CY, Huang HW, Chen SC, Hong CF, et al: Inhibition
of severe acute respiratory syndrome coronavirus replication by
niclosamide. Antimicrob Agents Chemother. 48:2693–2696. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Wen CC, Kuo YH, Jan JT, Liang PH, Wang SY,
Liu HG, Lee CK, Chang ST, Kuo CJ, Lee SS, et al: Specific plant
terpenoids and lignoids possess potent antiviral activities against
severe acute respi-ratory syndrome coronavirus. J Med Chem.
50:4087–4095. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Jurgeit A, McDowell R, Moese S, Meldrum E,
Schwendener R and Greber UF: Niclosamide is a proton carrier and
targets acidic endosomes with broad antiviral effects. PLoS Pathog.
8:e1002976. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Schweizer MT, Haugk K, McKiernan JS,
Gulati R, Cheng HH, Maes JL, Dumpit RF, Nelson PS, Montgomery B,
McCune JS, et al: A phase I study of niclosamide in combination
with enzalutamide in men with castration-resistant prostate cancer.
PLoS One. 13:e01983892018. View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Pizzorno A, Terrier O, Nicolas de
Lamballerie C, Julien T, Padey B, Traversier A, Roche M, Hamelin
ME, Rhéaume C, Croze S, et al: Repurposing of drugs as novel
influenza inhibitors from clinical gene expression infection
signatures. Front Immunol. 10:602019. View Article : Google Scholar : PubMed/NCBI
|
|
156
|
Rossignol J-F: Nitazoxanide, a new drug
candidate for the treatment of Middle East respiratory syndrome
coronavirus. J Infect Public Health. 9:227–230. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Shou J, Wang M, Cheng X, Wang X, Zhang L,
Liu Y, Fei C, Wang C, Gu F, Xue F, et al: Tizoxanide induces
autophagy by inhibiting PI3K/Akt/mTOR pathway in RAW264.7
macrophage cells. Arch Pharm Res. 43:257–270. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
158
|
Blaising J, Polyak SJ and Pécheur E-I:
Arbidol as a broad-spectrum antiviral: An update. Antiviral Res.
107:84–94. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
159
|
Haviernik J, Štefánik M, Fojtíková M, Kali
S, Tordo N, Rudolf I, Hubálek Z, Eyer L and Ruzek D: Arbidol
(Umifenovir): A broad-spectrum antiviral drug that inhibits
medically important arthropod-borne flaviviruses. Viruses.
10:1842018. View Article : Google Scholar :
|
|
160
|
Zhu Z, Lu Z, Xu T, Chen C, Yang G, Zha T,
Lu J and Xue Y: Arbidol monotherapy is superior to
lopinavir/ritonavir in treating COVID-19. J Infect. Apr
10–2020.Epub ahead of print. View Article : Google Scholar
|
|
161
|
Deng L, Li C, Zeng Q, Liu X, Li X, Zhang
H, Hong Z and Xia J: Arbidol combined with LPV/r versus LPV/r alone
against Corona Virus Disease 2019: A retrospective cohort study. J
Infect. Mar 11–2020.Epub ahead of print. View Article : Google Scholar
|
|
162
|
Lian N, Xie H, Lin S, Huang J, Zhao J and
Lin Q: Umifenovir treatment is not associated with improved
outcomes in patients with coronavirus disease 2019: A retrospective
study. Clin Microbiol Infect. Apr 25–2020.Epub ahead of print.
View Article : Google Scholar : PubMed/NCBI
|
|
163
|
Wang X, Cao R, Zhang H, Liu J, Xu M, Hu H,
Li Y, Zhao L, Li W, Sun X, et al: The anti-influenza virus drug,
arbidol is an efficient inhibitor of SARS-CoV-2 in vitro. Cell
Discov. 6:282020. View Article : Google Scholar : PubMed/NCBI
|
|
164
|
Crump A: Ivermectin: Enigmatic
multifaceted ′wonder′ drug continues to surprise and exceed
expectations. J Antibiot (Tokyo). 70:495–505. 2017. View Article : Google Scholar
|
|
165
|
Caly L, Druce JD, Catton MG, Jans DA and
Wagstaff KM: The FDA-approved drug ivermectin inhibits the
replication of SARS-CoV-2 in vitro. Antiviral Res. 178:1047872020.
View Article : Google Scholar : PubMed/NCBI
|
|
166
|
Yang SNY, Atkinson SC, Wang C, Lee A,
Bogoyevitch MA, Borg NA and Jans DA: The broad spectrum antiviral
ivermectin targets the host nuclear transport importin α/β1
heterodimer. Antiviral Res. 177:1047602020. View Article : Google Scholar
|
|
167
|
Juarez M, Schcolnik-Cabrera A and
Dueñas-Gonzalez A: The multitargeted drug ivermectin: From an
antiparasitic agent to a repositioned cancer drug. Am J Cancer Res.
8:317–331. 2018.PubMed/NCBI
|
|
168
|
Shen L, Niu J, Wang C, Huang B, Wang W,
Zhu N, Deng Y, Wang H, Ye F, Cen S, et al: High-throughput
screening and identification of potent broad-spectrum inhibitors of
Coronaviruses. J Virol. 93:e00023–e19. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
169
|
Dong HJ, Wang ZH, Meng W, Li CC, Hu YX,
Zhou L and Wang XJ: The natural compound Homoharringtonine presents
broad antiviral activity in Vitro and in Vivo. Viruses. 10:6012018.
View Article : Google Scholar :
|
|
170
|
Gordon DE, Jang GM, Bouhaddou M, Xu J,
Obernier K, White KM, O′Meara MJ, Rezelj VV, Guo JZ, Swaney DL, et
al: A SARS-CoV-2 protein interaction map reveals targets for drug
repurposing. Nature. Apr 30–2020.Epub ahead of print. View Article : Google Scholar
|
|
171
|
D′Elia RV, Harrison K, Oyston PC,
Lukaszewski RA and Clark GC: Targeting the 'cytokine storm' for
therapeutic benefit. Clin Vaccine Immunol. 20:319–327. 2013.
View Article : Google Scholar
|
|
172
|
Tay MZ, Poh CM, Rénia L, MacAry PA and Ng
LFP: The trinity of COVID-19: Immunity, inflammation and
intervention. Nat Rev Immunol. Apr 28–2020.Epub ahead of print.
View Article : Google Scholar : PubMed/NCBI
|
|
173
|
Petrakis D, Margină D, Tsarouhas K, Tekos
F, Stan M, Nikitovic D, Kouretas D, Spandidos DA and Tsatsakis A:
Obesity a risk factor for increased COVID-19 prevalence, severity
and lethality (Review). Mol Med Rep. 22:9–19. 2020.PubMed/NCBI
|
|
174
|
Velazquez-Salinas L, Verdugo-Rodriguez A,
Rodriguez LL and Borca MV: The role of interleukin 6 during viral
infections. Front Microbiol. 10:10572019. View Article : Google Scholar : PubMed/NCBI
|
|
175
|
Mehta P, McAuley DF, Brown M, Sanchez E,
Tattersall RS and Manson JJ; HLH Across Speciality Collaboration,
UK: COVID-19: Consider cytokine storm syndromes and
immunosuppression. Lancet. 395:1033–1034. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
176
|
Betts BC, St Angelo ET, Kennedy M and
Young JW: Anti-IL6-receptor-alpha (tocilizumab) does not inhibit
human monocyte-derived dendritic cell maturation or alloreactive
T-cell responses. Blood. 118:5340–5343. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
177
|
Reichert JM: Which are the antibodies to
watch in 2013? MAbs. 5:1–4. 2013. View Article : Google Scholar :
|
|
178
|
Chinese Clinical Trial Registry (ChiCTR):
A clinical study for the efficacy and safety of Adalimumab
Injection in the treatment of patients with severe novel
coronavirus pneumonia (COVID-19). Registration number:
ChiCTR2000030089. http://www.chictr.org.cn/showprojen.aspx?proj=49889.
Accessed February 22, 2020.
|
|
179
|
Kamimura D, Ishihara K and Hirano T: IL-6
signal transduction and its physiological roles: The signal
orchestration model. Rev Physiol Biochem Pharmacol. 149:1–38.
2003.PubMed/NCBI
|
|
180
|
Kaur S, Bansal Y, Kumar R and Bansal G: A
panoramic review of IL-6: Structure, pathophysiological roles and
inhibitors. Bioorganic Med Chem. 28:1153272020. View Article : Google Scholar
|
|
181
|
Rose-John S: IL-6 trans-signaling via the
soluble IL-6 receptor: Importance for the pro-inflammatory
activities of IL-6. Int J Biol Sci. 8:1237–1247. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
182
|
Chen N, Zhou M, Dong X, Qu J, Gong F, Han
Y, Qiu Y, Wang J, Liu Y, Wei Y, et al: Epidemiological and clinical
characteristics of 99 cases of 2019 novel coronavirus pneumonia in
Wuhan, China: A descriptive study. Lancet. 395:507–513. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
183
|
Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao
Y, Xie C, Ma K, Shang K, Wang W and Tian DS: Dysregulation of
immune response in patients with COVID-19 in Wuhan, China. Clin
Infect Dis. Mar 12–2020.Epub ahead of print.
|
|
184
|
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z,
Xiang J, Wang Y, Song B, Gu X, et al: Clinical course and risk
factors for mortality of adult inpatients with COVID-19 in Wuhan,
China: A retrospective cohort study. Lancet. 395:1054–1062. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
185
|
Jamilloux Y, Henry T, Belot A, Viel S,
Fauter M, El Jammal T, Walzer T, François B and Sève P: Should we
stimulate or suppress immune responses in COVID-19? Cytokine and
anti-cytokine interventions. Autoimmun Rev. May 4–2020.Epub ahead
of print. View Article : Google Scholar : PubMed/NCBI
|
|
186
|
Srirangan S and Choy EH: The role of
interleukin 6 in the pathophysiology of rheumatoid arthritis. Ther
Adv Musculoskelet Dis. 2:247–256. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
187
|
Alzghari SK and Acuña VS: Supportive
treatment with Tocilizumab for COVID-19: A systematic review. J
Clin Virol. 127:1043802020. View Article : Google Scholar : PubMed/NCBI
|
|
188
|
Sciascia S, Aprà F, Baffa A, Baldovino S,
Boaro D, Boero R, Bonora S, Calcagno A, Cecchi I, Cinnirella G, et
al: Pilot prospective open, single-arm multicentre study on
off-label use of tocilizumab in patients with severe COVID-19. Clin
Exp Rheumatol. May 1–2020.Epub ahead of print.
|
|
189
|
Bae SC and Lee YH: Comparison of the
efficacy and tolerability of tocilizumab, sarilumab, and sirukumab
in patients with active rheumatoid arthritis: A Bayesian network
meta-analysis of randomized controlled trials. Clin Rheumatol.
37:1471–1479. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
190
|
Russell B, Moss C, George G, Santaolalla
A, Cope A, Papa S and Van Hemelrijck M: Associations between
immune-suppressive and stimulating drugs and novel COVID-19 - a
systematic review of current evidence. Ecancermedicalscience.
14:10222020. View Article : Google Scholar
|
|
191
|
Dinarello CA: The IL-1 family and
inflammatory diseases. Clin Exp Rheumatol. 20(Suppl 27): S1–S13.
2002.
|
|
192
|
Sichelstiel A, Yadava K, Trompette A,
Salami O, Iwakura Y, Nicod LP and Marsland BJ: Targeting IL-1β and
IL-17A driven inflammation during influenza-induced exacerbations
of chronic lung inflammation. PLoS One. 9:e984402014. View Article : Google Scholar
|
|
193
|
Feldmann M, Maini RN, Woody JN, Holgate
ST, Winter G, Rowland M, Richards D and Hussell T: Trials of
anti-tumour necrosis factor therapy for COVID-19 are urgently
needed. Lancet. 395:1407–1409. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
194
|
Farsalinos K, Niaura R, Le Houezec J,
Barbouni A, Tsatsakis A, Kouretas D, Vantarakis A and Poulas K:
Editorial: Nicotine and SARS-CoV-2: COVID-19 may be a disease of
the nicotinic cholinergic system. Toxicol Rep. Apr 30–2020.Epub
ahead of print. View Article : Google Scholar : PubMed/NCBI
|
|
195
|
Berlin I, Thomas D, Le Faou AL and Cornuz
J: COVID-19 and smoking. Nicotine Tob Res. Apr 3–2020.Epub ahead of
print. View Article : Google Scholar : PubMed/NCBI
|
|
196
|
Arimori Y, Nakamura R, Yamada H, Shibata
K, Maeda N, Kase T and Yoshikai Y: Type I interferon limits
influenza virus-induced acute lung injury by regulation of
excessive inflammation in mice. Antiviral Res. 99:230–237. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
197
|
Lokugamage KG, Hage A, Schindewolf C,
Rajsbaum R and Menachery VD: SARS-CoV-2 sensitive to type I
interferon pretreatment. bioRxiv: :https://doi.org/10.1101/2020.03.07.982264.
|
|
198
|
Mantlo E, Bukreyeva N, Maruyama J,
Paessler S and Huang C: Antiviral activities of type I interferons
to SARS-CoV-2 infection. Antiviral Res. 179:1048112020. View Article : Google Scholar : PubMed/NCBI
|
|
199
|
Deftereos S, Giannopoulos G, Vrachatis DA,
Siasos G, Giotaki SG, Cleman M, Dangas G and Stefanadis C:
Colchicine as a potent anti-inflammatory treatment in COVID-19: can
we teach an old dog new tricks. Eur Hear J Cardiovasc Pharmacother.
Apr 27–2020.Epub ahead of print. View Article : Google Scholar
|
|
200
|
Hemilä H: Vitamin C and Infections.
Nutrients. 9:3392017. View Article : Google Scholar :
|
|
201
|
Cheng RZ: Can early and high intravenous
dose of vitamin C prevent and treat coronavirus disease 2019
(COVID-19)? Med drug Discov. 5:1000282020. View Article : Google Scholar : PubMed/NCBI
|
|
202
|
Marik PE, Kory P and Varon J: Does vitamin
D status impact mortality from SARS-CoV-2 infection? Med drug
Discov. Apr 29–2020.Epub ahead of print. View Article : Google Scholar :
|
|
203
|
Skalny AV, Rink L, Ajsuvakova OP, Aschner
M, Gritsenko VA, Alekseenko SI, Svistunov AA, Petrakis D, Spandidos
DA, Aaseth J, et al: Zinc and respiratory tract infections:
Perspectives for COVID 19 (Review). Int J Mol Med. 46:17–26.
2020.
|
|
204
|
Jayawardena R, Sooriyaarachchi P,
Chourdakis M, Jeewandara C and Ranasinghe P: Enhancing immunity in
viral infections, with special emphasis on COVID-19: A review.
Diabetes Metab Syndr. 14:367–382. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
205
|
Langsted A and Nordestgaard BG: Antisense
oligonucleotides targeting lipoprotein(a). Curr Atheroscler Rep.
21:302019. View Article : Google Scholar : PubMed/NCBI
|
|
206
|
Li Q: Nusinersen as a therapeutic agent
for spinal muscular atrophy. Yonsei Med J. 61:273–283. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
207
|
Kim J, Hu C, Moufawad El Achkar C, Black
LE, Douville J, Larson A, Pendergast MK, Goldkind SF, Lee EA,
Kuniholm A, et al: Patient-customized oligonucleotide therapy for a
rare genetic disease. N Engl J Med. 381:1644–1652. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
208
|
Moschos SA, Usher L and Lindsay MA:
Clinical potential of oligonucleotide-based therapeutics in the
respiratory system. Pharmacol Ther. 169:83–103. 2017. View Article : Google Scholar
|
|
209
|
Ng B, Cash-Mason T, Wang Y, Seitzer J,
Burchard J, Brown D, Dudkin V, Davide J, Jadhav V, Sepp-Lorenzino
L, et al: Intratracheal administration of siRNA triggers mRNA
silencing in the lung to modulate T cell immune response and lung
inflammation. Mol Ther Nucleic Acids. 16:194–205. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
210
|
Le ATH, Krylova SM, Kanoatov M, Desai S
and Krylov SN: Ideal-filter capillary electrophoresis (IFCE)
facilitates the one-step selection of aptamers. Angew Chem Int Ed
Engl. 58:2739–2743. 2019. View Article : Google Scholar
|
|
211
|
Yufa R, Krylova SM, Bruce C, Bagg EA,
Schofield CJ and Krylov SN: Emulsion PCR significantly improves
nonequilibrium capillary electrophoresis of equilibrium
mixtures-based aptamer selection: Allowing for efficient and rapid
selection of aptamer to unmodified ABH2 protein. Anal Chem.
87:1411–1419. 2015. View Article : Google Scholar
|
|
212
|
Abbott TR, Dhamdhere G, Liu Y, Lin X,
Goudy L, Zeng L, Chemparathy A, Chmura S, Heaton NS, Debs R, et al:
Development of CRISPR as a prophylactic strategy to combat novel
coronavirus and influenza. bioRxiv: :https://doi.org/10.1101/2020.03.13991307.
|
|
213
|
Schopman NCT, ter Brake O and Berkhout B:
Anticipating and blocking HIV-1 escape by second generation
antiviral shRNAs. Retrovirology. 7:522010. View Article : Google Scholar : PubMed/NCBI
|
|
214
|
Duncan GA, Kim N, Colon-Cortes Y,
Rodriguez J, Mazur M, Birket SE, Rowe SM, West NE, Livraghi-Butrico
A, Boucher RC, et al: An Adeno-Associated Viral Vector Capable of
Penetrating the Mucus Barrier to Inhaled Gene Therapy. Mol Ther
Methods Clin Dev. 9:296–304. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
215
|
Kurosaki F, Uchibori R, Mato N, Sehara Y,
Saga Y, Urabe M, Mizukami H, Sugiyama Y and Kume A: Optimization of
adeno-associated virus vector-mediated gene transfer to the
respiratory tract. Gene Ther. 24:290–297. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
216
|
Steines B, Dickey DD, Bergen J, Excoffon
KJ, Weinstein JR, Li X, Yan Z, Abou Alaiwa MH, Shah VS, Bouzek DC,
et al: CFTR gene transfer with AAV improves early cystic fibrosis
pig phenotypes. JCI Insight. 1:e887282016. View Article : Google Scholar :
|
|
217
|
Suhy DA, Kao SC, Mao T, Whiteley L, Denise
H, Souberbielle B, Burdick AD, Hayes K, Wright JF, Lavender H, et
al: Safe, long-term hepatic expression of anti-HCV shRNA in a
nonhuman primate model. Mol Ther. 20:1737–1749. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
218
|
Denise H, Moschos SA, Sidders B, Burden F,
Perkins H, Carter N, Stroud T, Kennedy M, Fancy SA, Lapthorn C, et
al: Deep sequencing insights in therapeutic shRNA processing and
siRNA target cleavage precision. Mol Ther Nucleic Acids.
3:e1452014. View Article : Google Scholar : PubMed/NCBI
|
